20/20 Biolabs, Inc. (AIDX) Cash Flow Statement
Where AIDX’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$1.92B
- Capital expenditures
- $0 0.0% of revenue
- Free cash flow
- −$1.92B −93,867.7% margin
- Returned to shareholders
- —
- Change in cash
- −$758.0M cash at year-end $1.03B
Cash from operations
−$1.92B
Other financing
+$1.16B
Change in cash
−$758.0M
Drawn to scale: where the cash came from and how it was used. Hover for values.
AIDX operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
AIDX cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$1.9M2016 | −$1.92B2025 | — | |
| Capital expenditures | $02016 | $02025 | — | |
| Free cash flow | −$1.9M2016 | −$1.92B2025 | — | |
| Free cash flow margin | −443.7%2016 | −93,867.7%2025 | −93,424.0 pts | |
| Operating cash flow / net income | −0.522021 | 2.652022 | +3.17 | |
| Stock-based compensation | $1.3M2023 | $516,1802025 | −37.1%/yr | |
| Capex / revenue | 0.0%2016 | 0.0%2025 | 0.0 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
AIDX cash flow by activity
OperatingInvestingFinancingChange in cash
AIDX net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
AIDX cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$3.74B | −$5.6M | −$6.4M | $2.2M | $2.1M | −$2.0M | −$2.4M | −$1.5M | −$1.3M | −$2.2M |
| Depreciation & amortization | $77,976 | $135,757 | $167,293 | $288,689 | $123,661 | $65,129 | $43,908 | $30,760 | $10,606 | $25,295 |
| Stock-based compensation | $516,180 | $2.2M | $1.3M | — | — | — | — | — | — | — |
| Change in working capital | $836,734 | $619,692 | $225,812 | $3.1M | −$3.3M | −$80,692 | $118,108 | $110,341 | $192,863 | $60,209 |
| Other non-cash items | $1.82B | $21,335 | $65,894 | $205,081 | $38,573 | $1 | $140,514 | $7,500 | $0 | $247,980 |
| Cash from operating activities | −$1.92B | −$2.6M | −$4.6M | $5.8M | −$1.1M | −$2.0M | −$2.1M | −$1.3M | −$1.1M | −$1.9M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | −$5 | −$9,382 | −$261,789 | −$228,147 | −$184,072 | −$2,292 | −$64,076 | −$5 | $0 |
| Acquisitions & other investing | — | — | −$34,382 | −$200,763 | −$3 | $1.6M | −$1.7M | −$372,097 | −$27,429 | −$76,870 |
| Cash from investing activities | — | — | −$43,764 | −$462,552 | −$228,150 | $1.5M | −$1.7M | −$436,173 | −$27,434 | −$76,870 |
| Financing activities | ||||||||||
| Net borrowing (repayment) | $988,472 | $0 | −$46,575 | — | — | — | — | — | — | — |
| Shares issued | $197,088 | $293,333 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $1.16B | $0 | $583 | $112,599 | $1.2M | $3.4M | $1.1M | $4.0M | $1.1M | $1.9M |
| Cash from financing activities | $1.16B | $293,333 | −$45,992 | $112,599 | $1.2M | $3.4M | $1.1M | $4.0M | $1.1M | $1.9M |
| Summary | ||||||||||
| Net change in cash | −$758.0M | −$2.3M | −$4.7M | $5.5M | −$113,723 | $2.8M | −$2.6M | $2.2M | $57,858 | $982,225 |
| Cash at end of period | $1.03B | $1.8M | $4.1M | $8.8M | $3.4M | $3.5M | $636,018 | $3.3M | $1.0M | $982,225 |
| Free cash flow | −$1.92B | −$2.6M | −$4.6M | $5.5M | −$1.3M | −$2.2M | −$2.1M | −$1.4M | −$1.1M | −$1.9M |
| Free cash flow margin | −93,867.7% | −148.3% | −325.6% | 50.1% | −13.5% | −95.3% | −737.1% | −497.6% | −338.7% | −443.7% |
| Capex / revenue | 0.0% | 0.0% | 0.7% | 2.4% | 2.4% | 7.9% | 0.8% | 23.1% | 0.0% | 0.0% |
| Operating cash flow / net income | — | — | — | 2.65 | −0.52 | — | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Jun '23 | Mar '23 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating activities | |||||||||
| Net income | −$1.6M | −$2.1M | −$1.3M | −$825,539 | −$840,933 | −$764,577 | −$1.2M | −$1.7M | −$2.0M |
| Depreciation & amortization | $16,686 | $14,811 | $17,874 | $19,224 | $19,266 | $21,612 | $31,575 | $39,995 | $53,864 |
| Stock-based compensation | $371,300 | $128,440 | $127,230 | $129,649 | $129,650 | $129,650 | $652,980 | — | — |
| Change in working capital | $156,185 | −$68,870 | $280,027 | $119,526 | $157,913 | $125,022 | $11,686 | $207,628 | −$152,647 |
| Other non-cash items | $410,905 | $757,303 | $370,973 | $171,485 | −$1 | $0 | $16,356 | $62,428 | $958,583 |
| Cash from operating activities | −$605,460 | −$1.3M | −$511,667 | −$385,655 | −$534,105 | −$488,293 | −$536,451 | −$1.4M | −$1.1M |
| Investing activities | |||||||||
| Capital expenditures | −$5,354 | −$5,354 | $0 | $0 | $0 | $0 | $0 | −$4,682 | $0 |
| Acquisitions & other investing | −$2,146 | $0 | — | — | — | — | — | $85,334 | −$102,916 |
| Cash from investing activities | −$7,500 | −$5,354 | — | — | — | — | — | $80,652 | −$102,916 |
| Financing activities | |||||||||
| Dividends paid | −$67,470 | −$54,192 | — | — | — | — | — | — | — |
| Net borrowing (repayment) | $0 | $250,000 | $411,911 | $506,561 | $0 | $70,000 | $0 | — | — |
| Shares issued | $1.0M | $5.0M | $4,750 | $0 | $0 | $192,338 | $110,026 | $0 | $0 |
| Other financing | $7,470 | −$708,382 | −$23,862 | $0 | $0 | $0 | $0 | −$15,558 | −$15,307 |
| Cash from financing activities | $940,000 | $4.5M | $392,799 | $506,561 | $0 | $262,338 | $110,026 | −$15,558 | −$15,307 |
| Summary | |||||||||
| Net change in cash | $327,041 | $3.2M | −$118,868 | $120,906 | −$534,105 | −$225,955 | −$426,425 | −$1.3M | $7.6M |
| Cash at end of period | $4.5M | $4.2M | $1.0M | $1.1M | $1.0M | $1.6M | $1.8M | $6.2M | $7.6M |
| Free cash flow | −$600,106 | −$1.3M | −$511,667 | −$385,655 | −$534,105 | −$488,293 | −$536,451 | −$1.4M | −$1.1M |
| Free cash flow margin | −82.1% | −364.8% | −95.1% | −92.3% | −99.8% | −88.2% | −100.1% | −420.1% | −270.6% |
| Capex / revenue | 0.7% | 1.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.4% | 0.0% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
AIDX cash generation
In fiscal 2025 (ended December 31, 2025), 20/20 Biolabs generated -$1.9 billion of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$1.9 billion, −93,867.7% of revenue. Cash and equivalents fell by $758.0 million over the year.
Related: AIDX income statement, AIDX balance sheet. See the AIDX stock overview for the latest quote and news.
AIDX cash flow FAQ
What is 20/20 Biolabs's free cash flow?
20/20 Biolabs's free cash flow was -$1.9 billion in fiscal 2025: -$1.9 billion of operating cash flow minus $0 of capital expenditures It was -$2.6 million a year earlier..
How much cash does 20/20 Biolabs generate from operations?
20/20 Biolabs generated -$1.9 billion of cash from operating activities in fiscal 2025.